Medpace Holdings, Inc. (MEDP)
POSITIVEFondamental
69
Prix
$611.79
Capitalisation boursière
$17.31B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$2.78B
12 derniers mois (au 30/06/2026)
Résultat net
$492M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$682M
Capitaux propres totaux
$459M
Passif total
$1.52B
Ratio de liquidité général
0.73
Couverture des intérêts
-
Dette/EBITDA
0.24
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$847.98
Prix actuel
$611.79
Marge de sécurité
+27.9%
Fourchette de juste valeur
$551.19 - $1144.77
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
36.39
ROE
98.3%
Ratio P/B
39.89
P/FCF
24.49
Marge brute
-
ROIC
74.1%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
74.1%
WACC
10.9%
ROIC − WACC
+63.2 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Critères d'analyse fondamentale
Réussi (17)
- EPS shows upward trend
- Price CAGR 32.92%
- ROIC 74.1%
- P/FCF 24.49
- Debt/Equity ratio
- Operating Margin 21.0%
- Positive Free Cash Flow
- CapEx intensity
- Debt/EBITDA
- Return on Tangible Assets
- ROE 110.1%
- Revenue Growth 5Y 22.3%
- Earnings Surprise avg 7.5%
- PEG Ratio 1.05
- Earnings Quality (OCF/NI) 1.53
- Share Dilution -7.8%
- Piotroski F-Score 6/9
Échoué (7)
- P/B Ratio 39.89
- Current Ratio
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Analyst Consensus 35% Buy
- Net Margin Trend 17.7% vs 18.7%
Indisponible (3)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Dr. August James Troendle M.D. | CEO, President & Chairman | 69 |
| Mr. Kevin M. Brady | CFO & Treasurer | 50 |
| Mr. Stephen P. Ewald J.D. | Chief Compliance Officer, General Counsel & Corporate Secretary | 56 |
| Mr. Brad W. Hansman | Executive Vice President of Operations | 42 |
| Ms. Lauren Morris | Associate Director of Investors Relations | - |
| Mr. Todd Meyers | Vice President of Business Development & Marketing | - |
| Mr. Weimin Gai MS | Senior Vice President of Biometrics | - |
| Mr. John T. Wynne MBA | Chief Business Officer | - |
| Ms. Reinilde Heyrman M.D. | Chief Medical Officer of Medical Department | 64 |
| Ms. Gina Leisring M.P.H. | Senior Vice President of Clinical Monitoring | - |
Risque d'audit
6
Risque du conseil
8
Risque de rémunération
4
Risque droits des actionnaires
5
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for MEDP, sourced from Markets Gazette.